Search company, investor...

Founded Year



Series C | Alive

Total Raised


Last Raised

$90M | 3 yrs ago

About Strata Oncology

Strata Oncology operates as a precision oncology company. The company offers services that integrate molecular profiling, decision support, and clinical trial participation into routine practice, providing care for cancer patients. Strata Oncology primarily serves healthcare providers, health systems, biopharma, and patients. It was founded in 2015 and is based in Ann Arbor, Michigan.

Headquarters Location

8192 Jackson Road Suite A

Ann Arbor, Michigan, 48103,

United States



Strata Oncology's Products & Differentiators


    StrataNGS is a clinically and analytically validated tissue-based comprehensive genomic profiling (CGP) test that assesses DNA and RNA in solid tumors. The test is optimized for small tumor tissue samples to provide more patients the opportunity to benefit from precision medicine. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. StrataNGS is covered for qualifying Medicare and Medicare Advantage patients across all solid tumors.


Research containing Strata Oncology

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Strata Oncology in 2 CB Insights research briefs, most recently on Dec 20, 2022.

Expert Collections containing Strata Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Strata Oncology is included in 4 Expert Collections, including Digital Health.


Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Digital Health 50

150 items

The winners of the third annual CB Insights Digital Health 150.


Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.


Oncology Tech

457 items

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.

Strata Oncology Patents

Strata Oncology has filed 2 patents.

The 3 most popular patent topics include:

  • autoimmune diseases
  • clusters of differentiation
  • diabetes
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA sequencing, Biotechnology, Genetics, Bioinformatics


Application Date


Grant Date



Related Topics

Molecular biology, DNA sequencing, Biotechnology, Genetics, Bioinformatics



Latest Strata Oncology News

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

Nov 8, 2023

ANN ARBOR, Mich.--(BUSINESS WIRE)--Strata Oncology, a next-generation precision oncology company enabling smarter cancer treatment, today announced that it is the recipient of the “Diagnostics Innovation Of The Year” award in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe. The awar

Strata Oncology Frequently Asked Questions (FAQ)

  • When was Strata Oncology founded?

    Strata Oncology was founded in 2015.

  • Where is Strata Oncology's headquarters?

    Strata Oncology's headquarters is located at 8192 Jackson Road, Ann Arbor.

  • What is Strata Oncology's latest funding round?

    Strata Oncology's latest funding round is Series C.

  • How much did Strata Oncology raise?

    Strata Oncology raised a total of $133M.

  • Who are the investors of Strata Oncology?

    Investors of Strata Oncology include Arboretum Ventures, Baird Capital, Merck Global Health Innovation Fund, Renaissance Venture Capital, Pfizer Venture Investments and 8 more.

  • Who are Strata Oncology's competitors?

    Competitors of Strata Oncology include Notable, Caris, Pangea Biomed, Tempus, Personal Genome Diagnostics and 7 more.

  • What products does Strata Oncology offer?

    Strata Oncology's products include StrataNGS and 4 more.

  • Who are Strata Oncology's customers?

    Customers of Strata Oncology include Ochsner Health, Metro-Minnesota Community Oncology Research Consortium (MMCORC), SCL Health, Kettering Health and Kaiser Permanente.


Compare Strata Oncology to Competitors

Perthera Logo

Perthera operates as a healthcare artificial intelligence company focusing on advancing precision medicine. The company offers an artificial intelligence (AI) enabled platform utilizing patient history and multi-omic testing results to match cancer patients with ranked therapy options, and accelerates clinical and therapeutic innovation. It was formerly known as Personalized Cancer Therapy. It primarily serves the healthcare industry in the oncology sector. It was founded in 2012 and is based in McLean, Virginia.

First Ascent Biomedical

First Ascent Biomedical provides health care solutions. It provides a software as a medical device (SaMD) service in a software as a service (SaaS) model that delivers artificial intelligence (AI) driven patient-specific cancer treatment plans in 3-4 weeks. It offers drug Selection, drug testing, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) sequencing, and personalized cancer treatment plans. It was founded in 2018 and is based in Beaverton, Oregon.

Genomic Expression Logo
Genomic Expression

Genomic Expression is a company focused on improving healthcare delivery and cancer treatment effectiveness through RNA sequencing in the biotechnology industry. The company's main service is the OneRNA™ test, which sequences RNA and links it to approved therapies and clinical trials, with the aim of detecting diseases, monitoring health, and aiding in the design of next-generation cures. The company primarily serves the healthcare industry. It was founded in 2009 and is based in New York, New York.


BostonGene is a biomedical software company focused on advanced patient analysis and personalized therapy decision making in the fight against cancer. The company's main services include performing sophisticated analytics to aid clinicians in evaluating viable treatment options based on each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics, and disease profile. BostonGene primarily sells to the healthcare industry, specifically in the field of oncology. It was founded in 2015 and is based in Waltham, Massachusetts.

Pangea Biomed

Pangea Biomed develops a multi-cancer and multi-therapy response predictor. It combines machine learning and deep ribonucleic acid (RNA) analysis to map tumor molecular signatures for personalized cancer care. The company aims to bring precision oncology to cancer patients through oncology drug development, and the empowerment of oncologists to treat patients. It was founded in 2018 and is based in Tel Aviv, Israel.

SimBioSys Logo

SimBioSys is a technology company focused on computational oncology, operating within the healthcare and software industries. The company's main service is a biophysical simulation technology that predicts tumor responses to therapy, providing physicians with a platform for individualized treatment planning and giving patients a tool for shared decision making. SimBioSys primarily sells to the healthcare industry. It was founded in 2018 and is based in Chicago, Illinois.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.